Log in to search using one of your social media accounts:

 

NovoCure wins expanded indications for Optune brain tumor-zapping device

NovoCure said it won expanded indications from the FDA and a new CE Mark indication in the European Union for its brain-tumor treating Optune device. The Optune device uses NovoCure’s “tumor treating fields,” which use low-intensity, intermediate-frequency alternating electric fields that limit cancer cell replication and kill cancer cells, the St. Helier, N.J.-based company said. The FDA granted NovoCure clearance for its Optune in combination with prescribed temozolomide for the treatment of adult patients with newly diagnosed glioblastomas. “Novocure is committed to helping patients with glioblastoma, and we are proud that Optune has been shown to offer patients such a significant improvement in both progression-free and overall survival. Glioblastoma is the most common form of primary brain cancer which, until now, has not seen any significant therapeutic improvements in over a decade. We’re thankful to the many patients, their caregivers and healthcare providers who partnered with us to develop a treatment that has finally led to a significant improvement in the outcomes for patients with glioblastoma,” CEO Asaf Danziger said in a press release. The clinical study that supported the expanded indication reported that patients treated with the device and drug lived an average of 3 months longer than those who only took the drug, the company said. The new indication was reviewed under the FDA’s priority review program which provides...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Food & Drug Administration (FDA) Oncology Radiosurgery Regulatory/Compliance NovoCure Source Type: news

Related Links:

Lena Tietjen has received hundreds of packages filled with books for her own reading library while she begins to receive treatment and care for an inoperable malignant brain tumor.
Source: ABC News: Health - Category: Consumer Health News Tags: Lifestyle Source Type: news
MicroRNA‑216b inhibits cell proliferation and invasion in glioma by directly targeting metadherin. Mol Med Rep. 2017 Oct 19;: Authors: Chen Z, Wu Y, Song S, Zhu X, Zhu J Abstract Glioma is a well‑known aggressive and malignant brain tumor, and accounts for ~30% of all brain and central nervous system tumors. A number of studies have indicated that the abnormal expression of specific microRNAs (miR) serves vital roles in the tumorigenesis and tumor development of human cancer, including glioma. miR‑216b has been studied in a number of types of cancer. However, the expression pattern, molecula...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
AbstractGlioblastoma multiforme (GBM) is the most common primary brain tumor in adults. A variety of targeted agents are being tested in the clinic including cancer vaccines, immunotoxins, antibodies and T cell immunotherapy for GBM. We have previously reported that IL-13 receptor subunits α1 and α2 of IL-13R complex are overexpressed in GBM. We are investigating the significance ofIL-13R α1 andα2 expression in GBM tumors. In order to elucidate a possible relationship betweenIL-13R α1 andα2 expression with severity and prognoses of subjects with GBM, we analyzed gene expression (by micro...
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
Medulloblastoma, an aggressive cancer of the cerebellum, is among the most common pediatric brain tumors. Approximately one-third of medulloblastomas are associated with misactivation of the Hedgehog (Hh) pathway. GLI family zinc finger 2 (GLI2) coordinates the Hh transcriptional program; however, the GLI2 targets that promote cancer cell proliferation are unknown. Here, we incorporated a Gli2-EGFP allele into 2 different genetic mouse models of Hh-associated medulloblastoma. Hh signaling induced GLI2 binding to the Cdk6 promoter and activated Cdk6 expression, thereby promoting uncontrolled cell proliferation. Genetic or p...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
Non‐adherent, 3‐dimensional sphere formation is used as an in vitro surrogate to evaluate cellular potential for tumour initiation and self‐renewal. To determine if a shared molecular program underlies the capacity for sphere formation by cells originating from diverse tumour types, we characterized molecular and functional properties of 10 independent cell lines derived from 3 ontogenetically distinct dog cancers: hemangiosarcoma, osteosarcoma and glial brain tumours. Genome‐wide gene expression profiling identified tumour‐of‐origin‐dependent patterns of adjustment to sphere formation in a uniform culture co...
Source: Veterinary and Comparative Oncology - Category: Veterinary Research Authors: Tags: ORIGINAL ARTICLE Source Type: research
A Boston biotech with a unique approach to treating an aggressive brain tumor, Ziopharm Oncology reported this weekend that its combination of experimental drugs has helped 15 patients survive about twice as long as they would have otherwise in an early-stage trial. Ziopharm (Nasdaq: ZIOP) reported the updated trial data in patients with recurrent glioblastoma at the Society for Neuro-Oncology this weekend. The 15 patients are all being treated with Ziopharm’s gene therapy, called Ad-RTS-hIL-12,…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Abstract Patients with primary or metastatic brain tumors are at increased risk of developing venous thromboses. However, the potential benefit of therapeutic anticoagulation in these patients must be weighed against the deadly complication of intracranial hemorrhage. In this review, we summarize available evidence and recent studies of intracranial bleeding risks in primary and metastatic tumors and the impact of therapeutic anticoagulation. We find that for the majority of primary and treated metastatic brain tumors, the risk of spontaneous bleeding is acceptable and not further increased by careful therapeutic ...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Approximately 75,000 cancers of the brain and central nervous system are newly diagnosed each year in the US.1 Gliomas are the most common type of primary brain tumor and these primary brain malignancies are classified by the World Health Organization into 4 different types (I-IV) depending on the grade or severity of these lesions.2 Glioblastoma (GBM), a grade IV malignancy, is the most common primary malignant brain tumor and represents up to 16% of all primary central nervous system neoplasms.
Source: Seminars in Roentgenology - Category: Radiology Authors: Source Type: research
Abstract Glioblastoma is an aggressive malignancy with a poor prognosis. The current standard of care for newly diagnosed glioblastoma patients includes surgery to the extent, temozolomide combined with radiotherapy, and alternating electric fields therapy. After recurrence, there is no standard therapy and survival is less than 9 months. Recurrent glioblastoma offers a unique opportunity to investigate new treatment approaches in a malignancy known for remarkable genetic heterogeneity, immunosuppressive microenvironment and partially permissive anatomical blood brain barrier (BBB). Results from three first-in-man...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Objective The aim of the study was to determine the relationships between functional outcomes, clinical symptoms, and health-related quality of life among patients with malignant brain tumors receiving interdisciplinary outpatient rehabilitation. Design A prospective study of 49 adults with malignant brain tumors participating in outpatient therapies was performed. Outcome measures included the Functional Assessment of Cancer Therapy-Brain (FACT-Br) for health-related quality of life and the Patient-Reported Outcome Measures Instrument Survey (PROMIS) Depression and Pain Behavior scales measured at admission, discharg...
Source: American Journal of Physical Medicine and Rehabilitation - Category: Rehabilitation Tags: Original Research Articles Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Health | Medical Devices | Neurology | Study | Temodar